Anti-EGFR Strategy for Colorectal Cancer: Searching for the Real Target

Author(s): A. Zaniboni, F. Meriggi.

Journal Name: Letters in Drug Design & Discovery

Volume 3 , Issue 8 , 2006

Submit Manuscript
Submit Proposal

Abstract:

The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable. The search for a reliable marker that would allow clinicians to select patients for cetuximab therapy remains a major challenge.

Keywords: Cetuximab, Colorectal cancer, Anti-EGFR therapy

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 3
ISSUE: 8
Year: 2006
Page: [541 - 543]
Pages: 3
DOI: 10.2174/157018006778194673
Price: $58